The combination oxycodone/paracetamol (North American trade name Percocet, generic Endocet
and Ratio-Oxycocet in Canada) is a combined opioid/non-opioid pain reliever used to treat moderate to severe acute (short-term) pain, marketed by Endo International plc, formerly Endo Pharmaceuticals.
The U.S. Food and Drug Administration first approved Percocet in 1976, under application ANDA 085106.
As of August 2014, Endo International produces Percocet in the following dosages. Percocet tablets are available in four combinations of oxycodone hydrochloride with 325 mg of paracetamol / acetaminophen, each having different appearances and usual maximum daily doses:
Due to the liver toxicity of paracetamol the manufacturer and FDA dosage guidelines suggest no more than 4000mg total of paracetamol be taken per day, which would be 12 or fewer Percocet tablets per day as each one contains 325mg .
On June 30, 2009, an FDA advisory panel recommended that Percocet, Vicodin, and every other combination of acetaminophen with narcotic analgesics be limited in their sales because of their contributions to an alleged 400 acetaminophen-related deaths in the United States each year, that were attributed to acetaminophen overdose and associated liver damage.
In December 2009, the Canadian Medical Association Journal reported a study finding a fivefold increase in oxycodone-related deaths in Ontario (mostly accidental) between 1991 and 2007 that led to a doubling of all opioid-related Ontario deaths over the same period.
In March 2017, US President Trump initiated the President’s Commission on Combating Drug Addiction and the Opioid Crisis. In July 2017, an interim report was published. Some excerpts: